试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery
编号:NCT05457842登记状态:提前终止企业 / 申办者:Astellas Pharma Inc
药物 / 成分:pudexacianinium chloride
登记的停止原因(原文):Company's strategic decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-20
Neoadjuvant PRRT With Y-90-DOTATOC in pNET
编号:NCT05568017登记状态:提前终止企业 / 申办者:European Institute of Oncology
药物 / 成分:peptide receptor radionuclide therapy with Y-90-DOTATOC
登记的停止原因(原文):Difficulty in recruiting patients also due to the pandemic period, presence of competitive studies.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-19
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
编号:NCT01217411登记状态:提前终止企业 / 申办者:National Cancer Institute (NCI)
药物 / 成分:Cognitive Assessment、Gamma-Secretase Inhibitor RO4929097、Laboratory Biomarker Analysis、Stereotactic Radiosurgery
登记的停止原因(原文):Other - Protocol moved to Administratively Complete
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-19
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
编号:NCT03166631登记状态:提前终止企业 / 申办者:Boehringer Ingelheim
药物 / 成分:BI 891065、BI 754091
登记的停止原因(原文):Not due to safety reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-19
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
编号:NCT03648372登记状态:提前终止企业 / 申办者:Takeda
药物 / 成分:TAK-981
登记的停止原因(原文):Enrolment Challenges
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-19
Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer
编号:NCT04217057登记状态:提前终止企业 / 申办者:Washington University School of Medicine
药物 / 成分:64Cu-DOTA-ECL1i
登记的停止原因(原文):Insufficient funding/staff
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-19
Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery
编号:NCT04630886登记状态:提前终止企业 / 申办者:Riley McLean
药物 / 成分:Tranexamic acid injection、Lidocaine Epinephrine
登记的停止原因(原文):Drug supply issues
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-19
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
编号:NCT05261490登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:maplirpacept (PF-07901801)、Pegylated Liposomal Doxorubicin (PLD)
登记的停止原因(原文):A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-19
A Controlled Human Rhinovirus Infection Study of 2-Deoxy-D-Glucose in Healthy Adults
编号:NCT06375772登记状态:提前终止企业 / 申办者:G.ST Antivirals GmbH
药物 / 成分:2-Deoxy-D-glucose、Placebo
登记的停止原因(原文):Re-calculated sample size
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-11-18
Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma
编号:NCT02512692登记状态:提前终止企业 / 申办者:Medical University of South Carolina
药物 / 成分:SIR-Spheres microspheres (Yttrium-90 Microspheres)、Gemcitabine、Cisplatin
登记的停止原因(原文):Enrollment closed by internal scientific review committee due to slow accrual.
查看官方原始记录 ↗